teplizumab治疗后EBV再激活相关继发性HLH一例
报告一例44岁唐氏综合征合并2型糖尿病(stage 2 T1D)患者,在接受14天teplizumab疗程后6天出现EBV再激活相关的继发性噬血细胞性淋巴组织细胞增生症(HLH)。EBV PCR峰值>2,000,000 copies/mL,HScore 238,经地塞米松和四剂利妥昔单抗治疗后临床、生化和病毒学恢复;12个月时仍为stage 2 T1D且无需胰岛素。因果关系无法确立,且缺乏治疗前EBV PCR。
要点
- teplizumab治疗后严重炎症恶化需警惕EBV再激活及继发性HLH。
- 唐氏综合征患者可能是teplizumab相关EBV再激活的高危宿主。
- 早期EBV PCR和HLH评估有助于及时干预。
核心结论
- 本病例记录了唐氏综合征患者在接受teplizumab治疗后出现EBV再激活相关继发性HLH,但因果关系无法确立。
研究设计与样本
- 病例报告:一例44岁男性唐氏综合征合并stage 2 T1D患者,接受14天teplizumab疗程后随访。
主要发现
- 完成14天teplizumab疗程后6天,患者出现呼吸、肝、肾功能衰竭。
- EBV PCR峰值>2,000,000 copies/mL,血清学证实再激活。
- 淋巴结活检显示EBV相关淋巴增殖,符合继发性HLH标准(HScore 238)。
- 经地塞米松和四剂每周利妥昔单抗治疗后,临床、生化和病毒学恢复。
- 12个月时患者临床稳定,仍为stage 2 T1D且未接受胰岛素治疗。
关键数值与推荐
- 继发性HLH标准满足,HScore 238。
- EBV PCR峰值>2,000,000 copies/mL。
临床怎么用
- teplizumab治疗后出现严重炎症恶化时,应早期进行EBV PCR和HLH评估。
局限性
- 因果关系无法确立。
- 缺乏治疗前EBV PCR,无法评估治疗开始时既存EBV DNA血症对不良结局的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Teplizumab delays progression from stage 2 to stage 3 type 1 diabetes (T1D). Epstein-Barr virus (EBV) reactivation after teplizumab is usually transient and mild. We report EBV reactivation-associated secondary hemophagocytic lymphohistiocytosis (HLH) in an adult with trisomy 21 who was treated with teplizumab. RESEARCH DESIGN AND METHODS: We describe the clinical course, virologic testing, histopathology, treatment, and follow-up of a 44-year-old man with trisomy 21 and stage 2 T1D after a 14-day teplizumab course. RESULTS: Six days after completion of the 14-day teplizumab course, he developed respiratory, hepatic, and renal failure. EBV PCR peaked at >2,000,000 copies/mL; serology confirmed reactivation. Lymph node biopsy showed EBV-associated lymphoproliferation, and criteria for secondary HLH were fulfilled (HScore 238). Dexamethasone and four weekly rituximab doses were associated with clinical, biochemical, and virologic recovery. At 12 months, he remained clinically stable with stage 2 T1D and no insulin treatment. CONCLUSIONS: This case documents EBV reactivation-associated secondary HLH after teplizumab treatment in a patient with trisomy 21. Causality cannot be established, and the absence of pretreatment EBV PCR limits assessment of whether preexisting EBV DNAemia at treatment initiation contributed to the poor outcome. The observation raises a plausible but unproven host-virus-drug interaction and supports early EBV PCR and HLH evaluation after severe inflammatory deterioration after teplizumab.
引用
- Klemann C, Kordonouri O. Fulminant Secondary HLH Following EBV Reactivation in an Adult With Trisomy 21 After Teplizumab Treatment for Stage 2 Type 1 Diabetes. Diabetes Care. 2026. PMID: 42520060. doi:10.2337/dc26-0543
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。